Zymergen
- 🦄Became a unicorn2018
- 📈Peak valuation$3 Billion ’21
- 💔Became a Unitard2021
- 💸Last valuation~$300M
How it happened
Zymergen used machine learning and automation to engineer microbes that produce novel materials, riding synthetic-biology hype to a roughly $3B valuation at its April 2021 IPO. Within months it disclosed that its lead product, the flexible-display film Hyaline, had hit technical problems and would generate essentially no revenue; the stock crashed more than 70% and the CEO was ousted. Employee reviews read like a post-mortem — brilliant scientists, they said, but no focus, a portfolio scattered across too many projects, and five layoff rounds amid constant reorgs; several recounted relocating cross-country only to be cut within months. Ginkgo Bioworks bought it for ~$300M in stock in 2022, and the remnant wound through Chapter 11 liquidation.
Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗. See our methodology.
Source: GEN / Seeking Alpha / SEC ($3B valuation at April 2021 IPO, $575M raised; lead product Hyaline failed technically, stock -70%+, CEO ousted; Ginkgo Bioworks all-stock acquisition ~$300M 2022; Chapter 11 / liquidation 2023)
